National Bank of Canada FI Has $75.05 Million Stock Position in Henry Schein, Inc. (NASDAQ:HSIC)

National Bank of Canada FI grew its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 102.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,084,511 shares of the company's stock after purchasing an additional 548,561 shares during the quarter. National Bank of Canada FI owned approximately 0.87% of Henry Schein worth $75,048,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in HSIC. Franklin Resources Inc. increased its holdings in shares of Henry Schein by 137.0% in the 4th quarter. Franklin Resources Inc. now owns 89,181 shares of the company's stock worth $6,171,000 after acquiring an additional 51,544 shares during the period. Alliancebernstein L.P. grew its position in Henry Schein by 21.0% in the 4th quarter. Alliancebernstein L.P. now owns 179,152 shares of the company's stock worth $12,397,000 after purchasing an additional 31,064 shares during the last quarter. Wellington Management Group LLP increased its stake in shares of Henry Schein by 12.6% in the fourth quarter. Wellington Management Group LLP now owns 6,902 shares of the company's stock valued at $478,000 after purchasing an additional 775 shares during the period. O Shaughnessy Asset Management LLC raised its holdings in shares of Henry Schein by 12.0% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 4,352 shares of the company's stock valued at $301,000 after buying an additional 468 shares during the last quarter. Finally, Physician Wealth Advisors Inc. acquired a new position in shares of Henry Schein during the fourth quarter worth approximately $138,000. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Henry Schein

In related news, Director Philip A. Laskawy sold 2,604 shares of Henry Schein stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $71.04, for a total value of $184,988.16. Following the transaction, the director now owns 24,805 shares of the company's stock, valued at approximately $1,762,147.20. This trade represents a 9.50 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Bradford C. Connett sold 4,036 shares of the company's stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $71.15, for a total transaction of $287,161.40. Following the sale, the chief executive officer now directly owns 62,688 shares of the company's stock, valued at $4,460,251.20. This represents a 6.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.14% of the stock is owned by insiders.

Henry Schein Price Performance

Shares of HSIC traded down $1.12 during mid-day trading on Friday, hitting $65.47. The company's stock had a trading volume of 2,362,489 shares, compared to its average volume of 1,585,938. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 0.82. The firm has a 50-day moving average price of $73.96 and a 200 day moving average price of $72.58. Henry Schein, Inc. has a fifty-two week low of $63.00 and a fifty-two week high of $82.49. The stock has a market capitalization of $8.13 billion, a price-to-earnings ratio of 26.94, a PEG ratio of 2.13 and a beta of 0.84.

Henry Schein (NASDAQ:HSIC - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.23 by ($0.04). Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The business had revenue of $3.19 billion during the quarter, compared to analyst estimates of $3.25 billion. During the same quarter last year, the firm posted $0.66 EPS. The company's quarterly revenue was up 5.8% compared to the same quarter last year. On average, research analysts predict that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on the company. Wells Fargo & Company initiated coverage on Henry Schein in a research report on Friday, February 14th. They issued an "equal weight" rating and a $80.00 target price on the stock. Barrington Research reissued an "outperform" rating and set a $90.00 price target on shares of Henry Schein in a report on Wednesday, February 26th. UBS Group cut their price objective on shares of Henry Schein from $83.00 to $80.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 26th. Bank of America upgraded shares of Henry Schein from an "underperform" rating to a "buy" rating and increased their target price for the company from $69.00 to $84.00 in a research report on Monday, January 6th. Finally, Jefferies Financial Group raised their target price on shares of Henry Schein from $77.00 to $80.00 and gave the company a "hold" rating in a research note on Thursday, January 23rd. Six research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $81.10.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.